ABSTRACT
BACKGROUND AND OBJECTIVE: Risankizumab - a humanized monoclonal antibody that targets the p19 subunit of IL-23 - has been recently approved to treat moderate-to-severe plaque psoriasis. Real-world data based on a representative pool of patients are currently lacking. OBJECTIVE: To assess the mid- and long-term safety and efficacy profile of risankizumab in patients with moderate-to-severe psoriasis in the routine clinical practice. METHODS: This was a retrospective and multicenter study of consecutive psoriatic patients on risankizumab from April 2020 through November 2022. The primary endpoint was the number of patients who achieved a 100% improvement in their Psoriasis Area and Severity Index (PASI) (PASI100) on week 52. RESULTS: A total of 510 patients, 198 (38.8%) women and 312 (61.2%) men were included in the study. The mean age was 51.7±14.4 years. A total of 227 (44.5%) study participants were obese (body mass index [BMI] >30kg/m2). The mean baseline PASI score was 11.4±7.2, and the rate of patients who achieved PASI100 on week 52, 67.0%. Throughout the study follow-up, 21%, 50.0%, 59.0%, and 66% of the patients achieved PASI100 on weeks 4, 16, 24, and 40, respectively. The number of patients who achieved a PASI ≤2 was greater in the group with a BMI ≤30kg/m2 on weeks 4 (P=.04), 16 (P=.001), and 52 (P=.002). A statistically significantly greater number of patients achieved PASI100 in the treatment-naïve group on weeks 16 and 52 (P=.001 each, respectively). On week 16 a significantly lower number of participants achieved PASI100 in the group with psoriatic arthropathy (P=.04). Among the overall study sample, 22 (4.3%) patients reported some type of adverse event and 20 (3.9%) discontinued treatment. CONCLUSIONS: Risankizumab proved to be a safe and effective therapy for patients with moderate-to-severe psoriasis in the routine clinical practice.
Subject(s)
Leukokeratosis, Hereditary Mucosal , Nevus , Doxycycline/therapeutic use , Humans , Mouth MucosaSubject(s)
Adalimumab/therapeutic use , Dermatologic Agents/therapeutic use , Etanercept/therapeutic use , Psoriasis/drug therapy , Psoriasis/pathology , Severity of Illness Index , Ustekinumab/therapeutic use , Adalimumab/adverse effects , Adult , Anti-Inflammatory Agents/adverse effects , Anti-Inflammatory Agents/therapeutic use , Body Weight , Dermatologic Agents/adverse effects , Female , Humans , Male , Middle Aged , Retrospective Studies , Time Factors , Treatment Outcome , Ustekinumab/adverse effectsSubject(s)
Lupus Erythematosus, Discoid/diagnosis , Lupus Erythematosus, Systemic/pathology , Vulvar Diseases/diagnosis , Adult , Aged , Anti-Inflammatory Agents/therapeutic use , Clobetasol/therapeutic use , Erythema/pathology , Female , Humans , Immunosuppressive Agents/therapeutic use , Keratosis/pathology , Lupus Erythematosus, Discoid/pathology , Lupus Erythematosus, Systemic/complications , Skin Ulcer/etiology , Vulvar Diseases/pathologyABSTRACT
Alemtuzumab is a monoclonal antibody that has been used to treat refractory cases of Sézary syndrome (SS) and advanced mycosis fungoides. We present 5 patients with SS who were treated with alemtuzumab between 2008 and 2012, with an overall response rate of 80% (40% partial response and 40% complete response). A regimen of 10mg administered subcutaneously was well tolerated with acceptable toxicity. The median duration of response was 13 months. However, one patient remains in complete remission after 67 months, a remarkable outcome given the low survival rate associated with SS. In conclusion, we believe that alemtuzumab may be useful in cases of SS refractory to other treatments. As there are no curative treatments for SS, alemtuzumab should be considered as a therapeutic option.
